Last reviewed · How we verify

NCT07331220: PADN-HFpEF

Pulmonary Artery Denervation for Heart Failure With Preserved Left Ventricular Ejection Fraction

Not yet recruiting NA Last updated 9 January 2026
What this trial tests

NA trial testing PADN in Heart Failure With Preserved Ejection Fraction in 310 participants. Not yet recruiting.

Timeline
30 December 2025
Primary endpoint
30 December 2028
30 December 2028

Quick facts

Lead sponsorNanjing First Hospital, Nanjing Medical University
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposetreatment
Enrollment310
Start date30 December 2025
Primary completion30 December 2028
Estimated completion30 December 2028
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Nanjing First Hospital, Nanjing Medical University

Who can join

Adults 18 to 85, any sex, with Heart Failure With Preserved Ejection Fraction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To assess the impact of PADN combined with guideline-directed medical therapy (GDMT) versus a sham procedure with GDMT on clinical outcomes in heart failure (HF) patients with preserved left ventricular ejection fraction (LVEF\>40%). Outcomes include cardiovascular death, HF-related rehospitalization, requirement for heart transplantation or need of valvular treatment or LVAD or pacemaker implantation, and worsening in outpatients (defined as requirement for intravenous therapy or diuretic intensification, including increasing the types or dose of diuretics).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of PADN

Trials testing the same drug.

Other recruiting trials for Heart Failure With Preserved Ejection Fraction

Currently open trials in the same condition.

Other Nanjing First Hospital, Nanjing Medical University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07331220.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing